CIK联合多西他赛治疗老年中晚期肺腺癌近期疗效  

Short-term Curative Effect of Elder Patients with Middle-late Lung Adenocarcinoma Treated by CIK Combined with Docetaxel

作　　者：王铭栋[1] 孟繁明[1] 李红姬[1] 杨丽[1] 

机构地区：[1]吉林省吉林市中心医院肿瘤科,132000

出　　处：《中国实用乡村医生杂志》2014年第23期50-51,共2页Chinese Practical Journal of Rural Doctor

摘　　要：目的观察CIK联合多西他赛治疗老年中晚期肺腺癌的近期疗效。方法28例老年肺腺癌患者分为联合组和对照组各14例，对照组只给予多西他赛治疗，联合组行CIK联合多西他赛序贯治疗。结果联合组有效率78.6%高于对照组的28.6%，差异有统计学意义（P＜0.05）。结论 CIK联合多西他赛序贯治疗老年中晚期肺腺癌，疗效显著，且毒副作用小，患者耐受好，是一种有效的治疗方法。ObjectiveTo observe the short-term curative effect of elder patients with middle-late lung adenocarcinoma treated by CIK combined with docetaxel.Methods28 elder patients with lung adenocarcinoma were divided into the control group（14 cases） and the combined group（14 cases）. The control group were treated by docetaxel, and the combined group were treated by CIK combined with docetaxel.Results The effective rate of the combined group was 78.6%, and the control group was 28.6%, there was a statistical signiifcance（P〈0.05）.ConclusionThe curative effects of elder patients with middle-late lung adenocarcinoma treated by CIK combined with docetaxel was well, which had less toxic and side effects, and better patients’ tolerance. It was an effective treatment method.

关 键 词：肺腺癌 治疗 CIK 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]